Pharmacotherapy of prostatitis

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 14, 2010, Pages 2319-2330

  Snow, Devon C ^a   Shoskes, Daniel A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Acute prostatitis; Chronic pelvic pain syndrome; Chronic prostatitis; Pharmacotherapy; Prostatitis

Indexed keywords

AMPICILLIN; AZTREONAM; CEFTRIAXONE; CERNITIN; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CIPROFLOXACIN PLUS TAMSULOSIN; CLAVULANATE PLUS TICARCILLIN; CLAVULANIC ACID; COTRIMOXAZOLE; DOXYCYCLINE; FINASTERIDE; GENTAMICIN; LEVOFLOXACIN; MEPARTICIN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; OFLOXACIN; PENTOSAN POLYSULFATE; PERMIXEN; PLANT EXTRACT; PREGABALIN; QUERCETIN; ROFECOXIB; TAMSULOSIN; TERAZOSIN; TICARCILLIN; TIMENTIN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANAPHYLAXIS; ANOREXIA; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BLOATING; BLOOD DYSCRASIA; CONVULSION; DIARRHEA; DISEASE CLASSIFICATION; DIZZINESS; DRUG EFFICACY; FATIGUE; FLUSHING; GASTROINTESTINAL SECRETION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERSENSITIVITY; INFLAMMATION; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE WARMTH; LIVER NECROSIS; MUSCLE CRAMP; NAUSEA; OUTCOME ASSESSMENT; PALLOR; PELVIS PAIN SYNDROME; PHOTOSENSITIVITY; PHYSIOTHERAPY; PROSTATITIS; PSYCHOSIS; RASH; RESTLESSNESS; REVIEW; SIDE EFFECT; SWEATING; TASTE DISORDER; TENDON RUPTURE; TREATMENT DURATION; URETHRAL CATHETERIZATION; URINE RETENTION; URTICARIA; VOMITING;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-ANTAGONISTS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIPSYCHOTIC AGENTS; COMPLEMENTARY THERAPIES; HUMANS; MALE; NEUROMUSCULAR AGENTS; PHYSICAL THERAPY MODALITIES; PHYTOTHERAPY; PROSTATITIS;

EID: 77956605953     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.495946     Document Type: Review

References (95)

1. McNaughton-Collins M, Stafford RS, O'Leary MP, et al. How common is prostatitis? A national survey of physician visits. J Urol 1998;159:1224-1228
2. Drach GW. Prostatitis: man's hidden infection. Urol Clin North Am 1975;2:499-520
3. Meares EM Jr, Stamey TA. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol 1968;5:492-518
4. Krieger JN, Nyberg LJ, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999;282:236-237
5. Schneider H, Ludwig M, Hossain HM, et al. The 2001 Giessen Cohort Study on patients with prostatitis syndrome-an evaluation of inflammatory status and search for microorganisms 10 years after a first analysis. Andrologia 2003;35:258-262
6. Meares EM Jr. Acute and chronic prostatitis: diagnosis and treatment. Infect Dis Clin North Am 1987;1:855-873
7. Nickel JC, Downey J, Clark J, et al. Antibiotic pharmacokinetics in the inflamed prostate. J Urol 1995;153:527-529
8. Neal DE Jr. Treatment of acute prostatitis. In: Nickel JC, editor, Textbook of prostatitis. Isis Medical Media, Oxford, UK; 1999. p. 279-284
9. Bjerklund Johansen T, Gruneberg RN, Guibert J, et al. The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Eur Urol 1998;34:457-466
10. Pontari MA. Inflammation and anti-inflammatory therapy in chronic prostatitis. Urology 2002;60:29-33
11. Naber KG, Soergel F. Antibiotic therapy rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue. Andrologia 2003;35:331-335
12. Bulitta J, Kinzig-Schippers M, Naber CK,et al. Limitations in the use of drug cocktails to compare the pharmacokinetics of drugs: Ciprofloxacin versus levofloxacin. 40th Interscience Conference on Antimicrobial Agents & 1 Chemotherapy (ICAAC). poster no. 506; 17-20 September 2000 Toronto, Canada.
13. Naber CK, Steghafner M, Kinzig-Schippers M, et al. Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400 milligrams to volunteers. Antimicrob Agents Chemother 2001;45:293-297
14. Cox CE, Marbury TC, Pittman WG, et al. A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis. Clin Ther 2002;24:223-236
15. Rib-X Pharmaceuticals [webpage on the internet]. New Haven, CT: Rib-X Pharm, Inc.; c2010 [updated Jan 2010, cited 2010 April 16th]. Available from: http://www.rib-x.com/pipeline/rx-3341
16. Krieger JN, Egan KJ. Comprehensive evaluation and treatment of 75 men referred to chronic prostatitis clinic. Urology 1991;38:11-19
17. Weidner W, Ludwig M. In: Weidner W, Madsen PO, Schiefer HG, editors, Prostatitis - etiopathology, diagnosis and therapy diagnostic management of chronic prostatitis. Springer, Berlin; 1994. p. 158-174
18. Schaeffer AJ, Wendel EF, Dunn JK, et al. Prevalence and significance of prostatic inflammation. J Urol 1981;125:215-219
19. Nickel JC, Shoskes D, Wang Y, et al. How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? J Urol 2006;176:119-124
20. Wagenlehner FM, Naber KG. Prostatitis: the role of antibiotic treatment. World J Urol 2003;21:105-108
21. Weidner W, Jantos C, Schiefer HG, et al. Semen parameters in men with and without proven chronic prostatitis. Arch Androl 1991;26:173-183
22. Stamey TA, Meares EM, Winningham G. Chronic bacterial prostatitis and the diffusion of drugs into the prostatic fluid. J Urol 1970;103:187-194
23. Madsen PO, Whalen PR. Interaction between antimicrobial agents and prostatic tissue extract and fluid. Infection 1978;6:75-77
24. Wagenlehner FM, Weidner W, Sorgel F, et al. The role of antibiotics in chronic bacterial prostatitis. Int J Antimicrob Agents 2005;26:1-7
25. Sorgel F, Kinzig M, Naber KG. Physiological disposition of macrolides. In: Bryskier AJ, Butzler J-P, Neu HC, Tulkens PM, editors, Macrolides. Chemistry, pharmacology and clinical uses. Arnette Blackwell, Paris; 1993. p. 421-431
26. Naber KG, Kinzig M, Sorgel F, et al. Penetration of ofloxacin into prostatic fluid, ejaculate and seminal fluid. Infection 1993;21:34-39
27. Kurzer E, Kaplan S. Cost effectiveness model comparing trimethoprim sulfamethoxazole and ciprofloxacin for the treatment of chronic bacterial prostatitis. Eur Urol 2002;42:163-166
28. Skerk V, Krhen I, Lisic M, et al. Comparative randomized pilot study of azithromycin and doxycycline efficacy in the treatment of prostate infection caused by Chlamydia trachomatis. Int J Antimicrob Agents 2004;24:188-191
29. Skerk V, Schonwald S, Krhen I, et al. Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. Int J Antimicrob Agents 2003;21:457-462
30. Naber KJ. Antibiotic treatment of chronic bacterial prostatitis. In: Nickel JC, editor, Textbook of prostatitis, ISIS Medical Media, Oxford, UK; 1999:283-292
31. Giannarini G, Tascini C, Selli C. Prulifloxacin: clinical studies of a broad-spectrum quinolone agent. Drugs 1996;51:137-160
32. Bundrick W, Heron SP, Ray P, et al. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. Urology 2003;62:537-541
33. Weidner W, Ludwig M, Brahler E, et al. Outcome of antibiotic therapy with ciprofloxacin in chronic bacterial prostatitis. Drugs 1999;58:103-106
34. Pfau A. The treatment of chronic bacterial prostatitis. Infection 1991;19:160-164
35. Nickel JC, Olson ME, Costerton JW. Rat model of experimental bacterial prostatitis. Infection 1991;19:126-130
36. Stamey TA, Bushby SRM, Bragonje J. The concentration of trimethoprim in prostatic fluid: non-ionic diffusion or active transport? J Infect Dis 1973;129:686-690
37. Barbalias GA, Nikiforidis G, Liatsikos EN. Alpha-blockers for the treatment of chronic prostatitis in combination with antibiotics. J Urol 1998;159:883-887
38. Shoskes DA, Zeitlin SI. Use of prostatic massage in combination with antibiotics in the treatment of chronic prostatitis. Prostate Cancer Prostatic Dis 1999;2:159-162
39. Boneff AN. Topical treatment of chronic prostatitis and premature ejaculation. Int Urol Nephrol 1972;4:183-186
40. Bahk JY, Hyun JS, Lee JY, et al. Concentration of ofloxacin in canine prostate tissue and prostate fluid after intraprostatic injection of biodegradable sustained-releasing microspheres containing ofloxacin. J Urol 2000;163:1560-1564
41. Yamamoto M, Hibi H, Shatoshi A, et al. Chronic bacterial prostatitis treated with intraprostatic injection of antibiotics. Scand J Urol Nephrol 1996;30:199-201
42. Baert L, Leonard A. Chronic bacterial prostatitis: 10 years of experience with local antibiotics. J Urol 1988;140:755-757
43. Jimenez-Cruz JF, Tormo FB, Gomez JG. Treatment of chronic prostatitis: intraprostatic antibiotic injections under echography control. J Urol 1988;139:967-970
44. Guercini F, Pajoncini C, Bard R, et al. Echoguided drug infiltration in chronic prostatitis: results of a multi-centre study. Arch Ital Urol Androl 2005;77:87-92
45. Shoskes DA, Landis JR, Wang Y, et al.; Chronic Prostatitis Collaborative Research Network Study Group. Impact of post-ejaculatory pain in men with category III chronic prostatitis/chronic pelvic pain syndrome. J Urol 2004;172:542-547
46. Schaeffer AJ, Wendel EF, Dunn JK, et al. Prevalence and significance of prostatic inflammation. J Urol 1981;125:215-219
47. Wenninger K, Heiman JR, Rothman I, et al. Sickness impact of chronic nonbacterial prostatitis and its correlates. J Urol 1996;155:965-968
48. McNaughton-Collins M, Pontari MA, O'Leary MP, et al. Quality of life is impaired in men with chronic prostatitis: the chronic prostatitis collaborative research network. J Gen Intern Med 2001;16:565-662
49. UPOINT clinical phenotype for chronic pelvic pain syndrome. [updated 2009-2010, cited 2010 April 16th]. Available from: http://www.Upointmd. com
50. Litwin MS, McNaughton-Collins M, Fowler FJ, et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. J Urol 1999;162:369-375
51. Nickel JC, Downey J, Clark J, et al. Levofloxacin treatment for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) in men: a randomized placebo controlled multi-center trial. J Urol 2003;62:614-617
52. Labro MT. Antibacterial agents - phagocytes: new concepts for old in immunomodulation. Int J Antimicrob Agents 1998;10:11-21
53. Bergogne-Berezin E. Interactions among antibiotics, bacteria and the human immune system: the clinical relevance of in vitro testing. J Chemother 1997;9:109-115
54. Kirby RS, Lowe D, Bultitude MI, et al. Intraprostatic urinary reflux: an aetiological factor in abacterial prostatitis. Br J Urol 1982;54:729-731
55. Sugaya K, Nishijima S, Miyazato M, et al. Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and -1D adrenergic receptor antagonists, on bladder activity in rats. Neurosci Lett 2002;328:74-76
56. Yokoyama O, Yusup A, Oyama N, et al. Improvement of bladder storage function by alpha1-blocker depends on the suppression of C-fiber afferent activity in rats. Neurourol Urodyn 2006;25:461-467
57. Cheah PY, Liong ML, Yuen KH, et al. Terazosin therapy for chronic prostatitis/ chronic pelvic pain syndrome: a randomized, placebo controlled trial. J Urol 2003;169:592-596
58. Mehik A, Alas P, Nickel JC, et al. Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind placebo controlled, pilot study. J Urol 2003;62:425-429
59. Nickel JC, Narayan P, MacKay, J, et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. J Urol 2004;171:1594-1597
60. Alexander RB, Propert KJ, Schaeffer AJ, et al. Chronic prostatitis collaborative research network: ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial. Ann Intern Med 2004;141:581-589
61. Chen Y, Wu X, Liu J, et al. Effects of a 6-month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial. World J Urol 2010. [Epub ahead of print]
62. Nickel JC, Krieger JN, McNaughton-Collins M, et al. Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. N Engl J Med 2008;359:2663-2673
63. Rugendorff EW, Weidner W, Ebeling L. Results of treatment with pollen extract (Cernilton N) in chronic prostatitis and prostatodynia. Br J Urol 1993;71:433-438
64. Wagenlehner FM, Schneider H, Ludwig M, et al. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. Eur Urol 2009;56:544-551
65. Shoskes DA. Use of the bioflavonoid quercetin in patients with longstanding chronic prostatitis. J Am Neutraceutic Assoc 1999;2:18-21
66. Shoskes DA, Zeitlin SI, Shahed A, et al. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo control trial. Urol 1999;54:960-963
67. Shahed AR, Shoskes DA. Oxidative stress in prostatic fluid of patients with chronic pelvic pain syndrome: correlation with gram positive bacterial growth and treatment response. J Androl 2000;21:669-675
68. Shahed AR, Shoskes DA. Correlation of beta-endorphin and prostaglandin e2 levels in prostatic fluid of patients with chronic prostatitis with diagnosis and treatment response. J Urol 2001;166:1738-1741
69. Reissigl AE, Djavan B, Pointner J, et al. Chronic prostatitis/chronic pelvic pain syndrome recurrence after initial effective phytotherapeutic treatment. J Urol 2005;173:S30
70. Canale D, Turchi P, Girogi PM, et al. Treatment of abacterial prostato-vasculitis with nimesulide. Drugs 1993;46:147-150
71. Dimitrakov JD, Tchitalov J, Dikov D. Efficacy and safety of corticosteroids in the treatment of CP/CPPS: a randomized double blind placebo controlled trial. J Urol 2004;171:61
72. Nickel JC, Pontari M, Moon T, et al. A randomized, placebo controlled multi-center study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic non-bacterial prostatitis. J Urol 2003;169:1045
73. Nickel JC, Forrest JB, Tomera K, et al. Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study. J Urol 2005;173:1252-1255
74. Nickel JC. 5-Alpha reductase therapy for chronic prostatitis. In: Nickel JC, editors, Textbook of prostatitis, Isis Medical Media, Oxford, UK; 1999. p. 333-337
75. Leskinen M, Lukkarinen O, Marttilla T. Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: a double-blind, placebo controlled, pilot study. Urology 1999;53:502-505
76. Nickel JC, Downey J, Pontari MA, et al. A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIa chronic nonbacterial prostatitis). BJU Int 2004;93:991-995
77. De Rose AF, Gallo F, Giglio M, et al. Role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized prospective placebo-controlled trial. Urology 2004;63:13-16
78. Pontari M, Krieger JN, Litwin MS, et al. A randomized placebo-controlled multicenter trial of pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome. J Urol 2009;181:123
79. Schaeffer AJ. Etiology and management of chronic pelvic pain syndrome in men. Urology 2004;63:75-84
80. Anderson RU. Treatment of prostatodynia (pelvic floor myalgia or chronic non-inflammatory pelvic pain syndrome). In: Nickel JC, editor, Textbook of prostatitis, ISIS Medical Media, Oxford, UK; 1999. p. 357-364
81. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85:S3-14
82. Anderson RU, Wise D, Sawyer T, et al. Integration of myofascial trigger point release and paradoxical relaxation training treatment of chronic pelvic pain in men. J Urol 2005;174:155-160
83. Anderson RU, Wise D, Sawyer T, et al. Sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome: improvement after trigger point release and paradoxical relaxation training. J Urol 2006;176:1534-8; discussion 1538-1539
84. FitzGerald MP, Anderson RU, Potts J, et al. Urological pelvic pain collaborative research network. Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes. J Urol 2009;182:570-580
85. Nickel JC, Downey J, Ardern D, et al. Failure of a monotherapy strategy for difficult chronic prostatitis/chronic pelvic pain syndrome. J Urol 2004;172:551-554
86. Shoskes DA, Hakim L, Ghoniem G, et al. Long-term results of multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome. J Urol 2003;169:1406-1410
87. Tugcu V, Tasci AI, Fazlioglu A, et al. A placebo-controlled comparison of the efficiency of triple- and monotherapy in category III B chronic pelvic pain syndrome (CPPS). Eur Urol 2007;51:1113-1117
88. Shoskes DA, Nickel JC, Rackley RR, et al. Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes. Prostate Cancer Prostatic Dis 2009;12:177-183
89. Shoskes DA, Nickel JC, Dolinga R, et al. Clinical phenotyping of patients with chronic prostatitis/chronic pelvic pain syndrome and correlation with symptom severity. Urology 2009;73:538-42; discussion 542-543
90. Nickel JC, Shoskes, D, Irvine-Bird, K, et al. Clinical phenotyping of women with interstitial cystitis/painful bladder syndrome: a key to classification and potentially improved management. J Urol 2009;182:155-160
91. Hedelin HH. Evaluation of a modification of the UPOINT clinical phenotype system for the chronic pelvic pain syndrome. Scand J Urol Nephrol 2009;43:373-376
92. Shoskes DA, Nickel JC, Kattan MW. Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT. Urology 2010. [Epub ahead of print]
93. Sandhu JS. Prostate cancer and chronic prostatitis. Curr Urol Rep 2008;9:328-332
94. Stopiglia RM, Ferreira U, Silva MM Jr, et al. Prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial. J Urol 2010;183:940-944
95. Shoskes DA. Chronic prostatitis/chronic pelvic pain syndrome: the status Quo is not good enough (but it can). UroToday Int J 2010; In press